pih1d2 Antibody

What is PIH1D2 and what are its known biological functions?

PIH1D2 (PIH1 Domain Containing 2) is a protein involved in several cellular processes, particularly related to protein complex formation and axonemal dynein assembly. Research suggests it functions as part of R2TP-like complexes involved in ciliary assembly and potentially in tumorigenesis.

The protein contains a PIH1 domain that represents the binding domain for RUVBL2 and other components in R2TP/Prefoldin-like complexes, which function as HSP90 co-chaperone complexes . Its involvement in dynein axonemal assembly has been demonstrated through immunoprecipitation studies showing interactions with multiple DNAAFs (Dynein Axonemal Assembly Factors), dynein chains, and canonical components of the R2TP complex . The estimated molecular weight of PIH1D2 is approximately 35.8 kDa , and it exists in multiple isoforms with potentially distinct functions.

What applications are PIH1D2 antibodies most commonly validated for?

PIH1D2 antibodies have been validated for multiple research applications, with specific performance characteristics depending on the host, clonality, and target epitope.

The most common validated applications include:

For optimal results, validation experiments should be performed when using PIH1D2 antibodies in new experimental systems. Antibody validation is particularly important as the detection efficiency can vary significantly based on sample preparation methods and the specific protein isoform being targeted .

How should researchers select between monoclonal and polyclonal PIH1D2 antibodies?

The selection between monoclonal and polyclonal PIH1D2 antibodies should be guided by the specific research application and experimental goals:

Monoclonal antibodies (e.g., clone OTI4A10, 5G9) offer:

• Higher specificity for a single epitope, reducing background and cross-reactivity

• Greater consistency between batches for longitudinal studies

• Superior performance in applications requiring high precision like flow cytometry

• Better suited for distinguishing between highly similar proteins or specific isoforms

Polyclonal antibodies provide:

For experimental designs requiring detection of specific PIH1D2 isoforms, consider antibodies targeting defined amino acid ranges. For example, antibodies targeting the C-terminal region (AA 220-249) have been validated for multiple applications across different species .

What are the optimal protocols for using PIH1D2 antibodies in Western blotting?

For successful Western blotting with PIH1D2 antibodies, consider the following optimized protocol:

• Sample preparation:

  • Use standard cell lysis buffers containing protease inhibitors

  • For detecting full-length PIH1D2 (35.8 kDa) and its isoforms (including 60 kDa and 94 kDa variants), prepare samples under reducing conditions

• Electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • For monoclonal antibodies: Dilute 1:1000 (recommended for OTI4A10 clone)

  • For polyclonal antibodies: Dilute 1:500-1:1000 depending on the specific antibody

  • Incubate primary antibody overnight at 4°C

• Detection optimization:

  • Use HRP-conjugated secondary antibodies or pre-conjugated primary antibodies for direct detection

  • For detecting low-abundance isoforms, consider enhanced chemiluminescence substrates

  • When analyzing multiple isoforms, run controls expressing recombinant PIH1D2 to confirm band identity

Note that PIH1D2 detection in Western blotting can be challenging in some cell types due to low endogenous expression levels. Validation using PIH1D2 knockout cell lines as negative controls is recommended for confirming specificity .

What are the critical factors for optimizing immunohistochemistry protocols with PIH1D2 antibodies?

Successful immunohistochemistry experiments using PIH1D2 antibodies require careful optimization of several parameters:

• Tissue preparation:

  • For paraffin-embedded tissues (IHC-p), use standard fixation with 10% neutral buffered formalin

  • Optimal antigen retrieval methods vary by antibody clone, but citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) with heat-induced epitope retrieval are most commonly effective

• Antibody selection and dilution:

  • For paraffin sections: Monoclonal antibodies like clone OTI4A10 at 1:150 dilution

  • For frozen sections: Dilutions may need to be adjusted (typically 1:50-1:100)

  • When staining for subcellular localization, PIH1D2 typically appears as cytoplasmic puncta (also described as dynein arm assembly particles or DynAPs)

• Detection system optimization:

  • For low expression tissues, utilize signal amplification systems like tyramide signal amplification

  • For double or triple labeling, consider using antibodies raised in different host species to avoid cross-reactivity

• Validation controls:

  • Include positive controls from tissues known to express PIH1D2

  • Use blocking peptides or PIH1D2 knockout tissues as negative controls

  • For studying ciliated tissues, consider co-staining with proximal cilia markers like ERICH3

A critical observation from published research is that PIH1D2 typically localizes in the cytoplasm as large puncta rather than in cilia, which can be an important control point for validating staining patterns .

How can researchers effectively validate the specificity of PIH1D2 antibodies?

Comprehensive validation of PIH1D2 antibodies requires multiple complementary approaches:

• Genetic knockout controls:

  • Use PIH1D2 knockout cell lines (such as HeLa PIH1D2-KO) as negative controls

  • Compare staining patterns between wild-type and knockout samples using identical protocols

  • Analyze multiple clones to rule out off-target effects

• Overexpression validation:

  • Transfect cells with PIH1D2 expression vectors and compare to empty vector controls

  • Western blotting of transfected vs. non-transfected cells should show enhanced signal at the expected molecular weight (35.8 kDa)

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide before application

  • Specific antibodies will show significantly reduced signal after peptide blocking

• Cross-application validation:

  • Confirm consistency of results across multiple applications (e.g., WB, IHC, and IP)

  • For antibodies claiming multiple species reactivity, test across those species

• Mass spectrometry validation:

  • For definitive validation, immunoprecipitate using the antibody and confirm target identity by mass spectrometry

  • This approach is particularly valuable for confirming the identity of different isoforms detected

Researchers should be aware that PIH1D2 exists in multiple isoforms, including a 60 kDa variant containing the C-terminal half but missing the N-terminal portion, which may complicate validation if antibodies target different regions .

What insights have been gained from PIH1D2 knockout models?

PIH1D2 knockout models have provided valuable insights into protein function and potential therapeutic applications:

• Cellular pathway analysis:

  • PIH1D2 knockout HeLa cells have revealed alterations in cellular functions and downstream effects on signaling pathways

  • These models allow researchers to dissect pathways impacted by PIH1D2 absence without the background interference of normal PIH1D2-mediated functions

• Tumorigenesis investigation:

  • Knockout models have enabled assessment of PIH1D2's impact on tumorigenesis mechanisms

  • Studies using these models have implicated PIH1D2 in chromatin remodeling processes with potential relevance to cancer biology

• Drug development applications:

  • PIH1D2 knockout cell lines serve as tools for identifying potential therapeutic targets in cancer treatment

  • These models allow testing of pharmacological agents in the absence of PIH1D2 function

• Experimental methodology:

  • Implementation typically involves standard transfection protocols to disrupt the PIH1D2 gene

  • Validation of knockout clones is performed through PCR and Western blotting

  • Comparison between knockout and wildtype phenotypes helps elucidate gene-specific functions

These knockout models address the critical need for gene-specific analysis in protein complexes where multiple components have overlapping functions, enhancing experimental accuracy in studies of PIH1D2's biological roles.

What is the relationship between PIH1D2 and axonemal dynein assembly mechanisms?

PIH1D2 appears to function within the context of axonemal dynein assembly, particularly in relation to R2TP-like complexes:

• R2TP complex association:

  • PIH1D2 contains domains that represent binding sites for RUVBL2 and other components in R2TP/Prefoldin-like complexes

  • It likely serves as part of HSP90 co-chaperone complexes involved in protein assembly and stability

• Dynein assembly pathway integration:

  • Research suggests PIH1D2 may function similarly to related proteins like PIH1D3, which has been established as a dynein axonemal assembly factor (DNAAF)

  • Immunoprecipitation studies have shown interactions between PIH1D2 and other DNAAFs, though some findings were limited by "less than optimal immunoprecipitation conditions"

• Ciliary function connections:

  • While PIH1D2 itself has not been directly implicated in ciliopathies like primary ciliary dyskinesia (PCD), related proteins in the same family show clear connections

  • The protein appears to localize in cytoplasmic dynein arm assembly particles (DynAPs) rather than in cilia themselves

• Molecular interactions:

  • PIH1D2 may participate in the R2TP-like complexes that assist in the formation of dynein subunit complexes

  • These complexes help fold and/or bind dynein heavy chains (DHCs) to dynein intermediate chain (DIC) complexes

The study of PIH1D2's specific role in these processes is still developing, with current evidence suggesting functional similarity to other PIH domain proteins involved in macromolecular complex assembly.

How can researchers design co-immunoprecipitation experiments to identify PIH1D2 interaction partners?

Designing effective co-immunoprecipitation (co-IP) experiments with PIH1D2 antibodies requires careful consideration of several technical factors:

• Antibody selection for IP:

  • Choose antibodies specifically validated for immunoprecipitation

  • Polyclonal antibodies often perform better in IP applications than monoclonals

  • Consider using antibodies targeting different epitopes to confirm interactions and rule out epitope masking

• Optimization of lysis conditions:

  • Use non-denaturing lysis buffers to maintain protein-protein interactions

  • Include protease and phosphatase inhibitors to prevent degradation

  • Adjust salt and detergent concentrations to balance extraction efficiency with preservation of interactions

  • Consider crosslinking approaches for transient interactions

• Experimental controls:

  • Include isotype control antibodies for monoclonal IP experiments

  • Use pre-immune serum controls for polyclonal antibodies

  • Perform reciprocal IPs when antibodies are available for suspected interaction partners

  • Include PIH1D2 knockout cells as negative controls

• Identification of interacting proteins:

  • For targeted analysis, use Western blotting to detect specific suspected interaction partners

  • For unbiased discovery, use mass spectrometry analysis of IP samples

  • Consider SILAC or other quantitative proteomics approaches to distinguish specific from non-specific interactions

• Overcoming technical challenges:

  • If initial experiments show weak signals, consider overexpression systems

  • For detecting interactions with dynein components or R2TP complex members, optimize buffer conditions based on published protocols

  • Be aware that some interactions may require additional cofactors or post-translational modifications

Previous research has shown that PIH1D2 interactions with DNAAFs and other proteins can be challenging to detect, possibly requiring optimization beyond standard protocols .

What methodologies are recommended for studying different PIH1D2 isoforms?

Investigating PIH1D2 isoforms requires specialized methodological approaches:

• Isoform identification:

  • Western blotting using antibodies targeting different regions of PIH1D2 can reveal distinct isoforms

  • Research has identified a full-length isoform (~35.8 kDa), a 94-kDa isoform, and a 60-kDa C-terminal isoform lacking the N-terminal portion

  • Select antibodies that recognize epitopes present in the specific isoforms of interest

• Targeted proteomics approaches:

  • For definitive isoform identification, gel isolation of bands followed by mass spectrometry analysis

  • Design peptide detection methods covering different regions of the protein

  • Example: Previous research detected peptides corresponding only to the C-terminal half of PIH1D2 in a 60-kDa band, confirming it as a C-terminal isoform

• RNA analysis for isoform expression:

  • RT-PCR using primers spanning different exon junctions can identify splice variants

  • RNA-seq analysis can provide comprehensive isoform detection and quantification

  • Targeted sequencing of transcripts can identify novel splicing events or mutations affecting isoform expression

• Functional differentiation:

  • Create expression constructs for specific isoforms to study their functions independently

  • Use isoform-specific knockdown approaches (siRNA or CRISPR) targeting unique regions

  • Compare subcellular localization patterns of different isoforms through immunofluorescence

• Cell type-specific expression analysis:

  • Different isoforms may show tissue or cell-type specific expression patterns

  • Example: The 60-kDa isoform is present in both undifferentiated and differentiated human bronchial epithelial cells, while full-length and 94-kDa isoforms appear only after differentiation

Understanding these isoforms is crucial as they may have distinct or partially overlapping functions, as demonstrated by the ability of the 60-kDa isoform to partially compensate for the absence of full-length PIH1D2 in certain contexts .

What strategies can overcome challenges in PIH1D2 detection in different subcellular compartments?

Detecting PIH1D2 in different subcellular compartments presents unique challenges that can be addressed through optimized methodologies:

• Subcellular fractionation optimization:

  • Use differential centrifugation to separate cytoplasmic, nuclear, and membrane fractions

  • For studying PIH1D2 in dynein assembly particles (DynAPs), consider density gradient centrifugation

  • Validate fractionation quality using markers for specific compartments (e.g., GAPDH for cytoplasm, Lamin A/C for nucleus)

• Immunofluorescence microscopy approaches:

  • PIH1D2 typically appears as cytoplasmic puncta (DynAPs)

  • Use confocal microscopy with Z-stacking to precisely locate these punctate structures

  • Co-stain with markers of specific compartments to establish localization context

  • Consider super-resolution microscopy for detailed analysis of DynAP structures

• Fixation and permeabilization optimization:

  • Different fixatives (PFA vs. methanol) may reveal different aspects of PIH1D2 localization

  • Test multiple permeabilization protocols, as some may better preserve protein complexes

  • For detection in ciliated cells, co-stain with proximal cilia markers like ERICH3

• Signal enhancement techniques:

  • For low abundance expression, use tyramide signal amplification or similar methods

  • Consider proximity ligation assays (PLA) to detect PIH1D2 interactions with known partners in situ

  • For time-course studies, photoconvertible fusion proteins may help track protein movement

• Antibody panel approach:

  • Use multiple antibodies targeting different epitopes to confirm localization patterns

  • Consider the different isoforms (35.8 kDa, 60 kDa, 94 kDa) which may localize differently

  • Account for potential masking of epitopes in protein complexes

Research has demonstrated that PIH1D2 is exclusively cytoplasmic and absent from ciliary axonemes, despite its involvement in dynein arm assembly, which is critical information for experimental design and interpretation .

How can researchers apply PIH1D2 antibodies in studies of chromatin remodeling and tumorigenesis?

PIH1D2 has been implicated in chromatin remodeling and tumorigenesis processes, with specific methodological approaches recommended for these research areas:

• Chromatin association studies:

  • Use chromatin immunoprecipitation (ChIP) to investigate potential associations with chromatin

  • Combine with sequencing (ChIP-seq) for genome-wide analysis of binding sites

  • Consider ChIP-mass spectrometry to identify chromatin-associated PIH1D2 complexes

• Cancer cell line analysis:

  • Compare PIH1D2 expression and localization across cancer cell lines with different malignant properties

  • Use PIH1D2 knockout cell lines to assess changes in malignant phenotypes

  • Apply antibodies in cell-based phenotypic assays to correlate expression with cancer-related behaviors

• Tumor tissue analysis:

  • Optimize immunohistochemistry protocols for PIH1D2 detection in tumor tissue microarrays

  • Correlate expression patterns with clinical parameters and outcomes

  • Consider multiplexed immunofluorescence to study PIH1D2 in the tumor microenvironment context

• Mechanistic investigations:

  • Use proximity-based methods (BioID, APEX) with PIH1D2 as bait to identify cancer-relevant interactors

  • Apply CRISPR screens in PIH1D2-expressing vs. knockout backgrounds to identify synthetic lethality partners

  • Conduct drug screening in matched PIH1D2-expressing and knockout cells to identify PIH1D2-dependent vulnerabilities

• Technical considerations for cancer studies:

  • Ensure antibody validation in the specific cancer models used (different tumor types may show different PIH1D2 isoform expression)

  • For patient-derived xenografts or primary samples, test antibody cross-reactivity with host species proteins

  • Consider potential post-translational modifications in cancer contexts that might affect antibody recognition

PIH1D2 knockout cell lines are particularly valuable for these studies as they "enable precise modeling of disease mechanisms and the response to various pharmacological agents," providing focused insights without background interference from normal PIH1D2 functions .

What are the recommended approaches for using PIH1D2 antibodies in multiplexed assays?

Multiplexed analysis with PIH1D2 antibodies requires specific technical considerations to ensure specificity and compatibility:

• Antibody panel design for flow cytometry:

  • Use fluorophore-conjugated PIH1D2 antibodies for multiparameter analysis

  • Select fluorophores with minimal spectral overlap when combining with other markers

  • Consider the following dilution guidance for flow cytometry: 1:100 for monoclonal antibodies like OTI4A10

  • Validate compensation settings with single-stained controls

• Multiplexed immunofluorescence microscopy:

  • Select PIH1D2 antibodies raised in different host species than other target antibodies

  • For same-species antibodies, use directly labeled primary antibodies or sequential staining with blocking steps

  • Consider tyramide signal amplification methods for multiplexed detection with signal enhancement

  • Use spectral imaging systems to separate overlapping fluorophores when needed

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated PIH1D2 antibodies can be incorporated into large CyTOF panels

  • Test antibody performance after metal conjugation as this may affect binding properties

  • Validate with positive and negative control samples (including PIH1D2 knockout cells)

• Multiplex Western blotting:

  • Use differentially labeled secondary antibodies for simultaneous detection of multiple proteins

  • Consider size differences between targets to avoid signal overlap (PIH1D2: ~35.8 kDa)

  • For detecting multiple PIH1D2 isoforms simultaneously, use antibodies targeting conserved regions

• Advanced spatial proteomics:

  • For CODEX or similar highly multiplexed imaging platforms, validate PIH1D2 antibody performance in the specific assay context

  • Consider epitope retrieval compatibility when combining with other antibodies

  • Test for potential cross-reactivity with other panel components

When designing multiplexed experiments, careful consideration of controls is essential, particularly when studying PIH1D2 in relation to its potential interaction partners in R2TP complexes or dynein assembly pathways .

How should researchers interpret discrepancies in PIH1D2 antibody data between different experimental systems?

When faced with discrepancies in PIH1D2 antibody results across different experimental systems, consider these methodological approaches for resolution:

• Antibody validation across systems:

  • Verify antibody performance in each experimental system independently

  • Include appropriate positive and negative controls specific to each system

  • Consider epitope availability differences between applications (native vs. denatured protein)

• Isoform expression analysis:

  • Different experimental systems may express different PIH1D2 isoforms

  • The full-length (35.8 kDa), 94-kDa, and 60-kDa isoforms may show tissue-specific or differentiation-dependent expression

  • Verify which epitopes are present in the expressed isoforms relative to antibody binding sites

• Technical variable assessment:

  • Systematically evaluate sample preparation methods (fixation, lysis, etc.)

  • Test multiple antibody concentrations and incubation conditions

  • Consider buffer compatibility issues that may affect antibody performance

• Comprehensive analysis approaches:

  • Triangulate results using multiple antibodies targeting different epitopes

  • Complement antibody-based detection with mRNA analysis

  • Consider orthogonal methods like mass spectrometry for definitive protein identification

• Data resolution strategies:

  • For contradictory subcellular localization data, use fractionation followed by Western blotting

  • For discrepancies in interaction partners, consider crosslinking approaches to stabilize transient interactions

  • When antibody-based methods yield inconsistent results, genetic approaches (CRISPR knockout/knockin) can provide clarity

Research has demonstrated that PIH1D2 expression and detection can vary significantly based on cell differentiation state, with some isoforms appearing only in differentiated epithelial cells while others are present throughout differentiation . Such biological variability may explain seemingly contradictory experimental results.